Univest
Univest
  • Markets

Aarti Surfactants Analyst Review 2027: Six Months of FY27 Have Already Out-Earned All of FY26

  • November 17, 2026
  • Posted by: Ankit Jaiswal
  • Category: Market
No Comments
Aarti Surfactants Analyst Review 2027: Six Months of FY27 Have Already Out-Earned All of FY26

Aarti Surfactants Stock Snapshot (16 Nov 2026 close)

  • Current Market Price (CMP): ₹582.75
  • 52-Week High / Low: ₹677.70 / ₹316.00
  • Market Capitalisation: ₹492 crore
  • P/E Ratio vs Industry P/E: 16.8 vs 33.4
  • Latest Quarter (Q2 FY27) Revenue: ₹291.4 crore
  • Latest Quarter (Q2 FY27) Net Profit: ₹12.5 crore

Quick Answer: The Aarti Surfactants analyst review 2027 is about a fast earnings recovery. Q2 FY27 revenue rose about 63% to ₹291.4 crore and profit rose to ₹12.5 crore from ₹1.56 crore, so first-half profit of about ₹21.5 crore already beats FY26’s full-year ₹12.3 crore. EBITDA margin climbed to 8.8% from 5.3%. No brokerage covers the stock, so there is no published Aarti Surfactants share price target 2027. At ₹582.75 the stock trades at a P/E of about 16.8, half its industry, and about 14% below its 52-week high.

The Aarti Surfactants analyst review 2027 centres on a single comparison: in the first six months of FY27 the company earned more than in all twelve months of FY26. For anyone searching for an Aarti Surfactants share price target 2027, it is important to know that no research firm publishes one, so this review rests on company numbers.

Aarti Surfactants closed at ₹582.75 on 16 November 2026, about 14% below its 52-week high of ₹677.70 and 84% above its low of ₹316. This Aarti Surfactants analyst review 2027 covers the quarter, the business, balance sheet, ownership and the factors that will shape the Aarti Surfactants stock outlook 2027.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • What Analysts Say in the Aarti Surfactants Analyst Review 2027
  • Q2 FY27 Results in the Aarti Surfactants Analyst Review 2027
  • How Aarti Surfactants Makes Money
  • Growth Triggers in the Aarti Surfactants Analyst Review 2027
  • Key Risks in the Aarti Surfactants Analyst Review 2027
  • Aarti Surfactants Analyst Review 2027: Stock at a Glance
  • Shareholding Trend
  • What to Watch After the Aarti Surfactants Analyst Review 2027
  • Final Word on the Aarti Surfactants Analyst Review 2027
  • Frequently Asked Questions
    • What does the Aarti Surfactants analyst review 2027 show?
    • Is there an Aarti Surfactants share price target 2027 from brokerages?
    • Why did profit jump in the Aarti Surfactants analyst review 2027 quarter?
    • What does Aarti Surfactants make?
    • Is Aarti Surfactants undervalued, according to the Aarti Surfactants analyst review 2027?
    • What risks does the Aarti Surfactants analyst review 2027 highlight?
    • What should investors track after the Aarti Surfactants analyst review 2027?

What Analysts Say in the Aarti Surfactants Analyst Review 2027

Brokerage Rating Target Price Date
No verified coverage Not available Not available As of November 2026

We found no dated brokerage report on Aarti Surfactants. With a market value of about ₹492 crore and almost no institutional ownership, it sits outside most research coverage.

That shapes the Aarti Surfactants analyst review 2027. Price discovery depends on results and on retail and promoter activity, and any Aarti Surfactants share price target 2027 that does not name a registered research firm should be treated as opinion.

Q2 FY27 Results in the Aarti Surfactants Analyst Review 2027

Quarter Revenue EBITDA Net Profit Operating Margin
Sep 2026 (Q2 FY27) ₹291.4 crore ₹30.0 crore ₹12.5 crore 8.8%
Jun 2026 (Q1 FY27) ₹273.0 crore ₹20.5 crore ₹9.0 crore 7.5%
Mar 2026 (Q4 FY26) ₹256.5 crore ₹13.4 crore ₹4.2 crore 5.2%
Dec 2025 (Q3 FY26) ₹207.8 crore ₹12.7 crore ₹3.7 crore 6.1%
Sep 2025 (Q2 FY26) ₹179.2 crore ₹9.4 crore ₹1.6 crore 5.3%

Every line in the Aarti Surfactants analyst review 2027 table moves the same way. Revenue has risen for four straight quarters, from ₹179 crore to ₹291 crore. EBITDA has more than tripled over the same period, and the margin has climbed from about 5% to almost 9%.

Profit grew even faster because a surfactant maker has meaningful fixed costs. Once volumes rise, each extra tonne adds more to profit. Earnings per share for Q2 were about ₹14.75, compared with about ₹1.84 a year earlier.

How Aarti Surfactants Makes Money

Aarti Surfactants was separated from Aarti Industries and is part of the Aarti group. It makes surfactants, the cleaning and foaming ingredients found in shampoos, body washes, detergents and dishwashing liquids. Its business has three parts:

  • Surfactants: anionic, non-ionic and other types sold to home and personal care brands.
  • Specialty ingredients: higher-value additives for skin care and hair care.
  • Contract and private label manufacturing: through its wholly owned subsidiary Aarti HPC.

Profit depends on volumes sold to large consumer goods companies and on the spread over raw materials such as fatty alcohols and petrochemical feedstocks. The company says sales have compounded at about 14% a year over six years. For the Aarti Surfactants analyst review 2027, the shift towards specialty products is what lifts margins.

Growth Triggers in the Aarti Surfactants Analyst Review 2027

  • Volume momentum: four quarters of rising revenue show demand from customers recovering.
  • Margin recovery: operating margin near 9% is the best in the five quarters shown.
  • Fixed cost absorption: higher utilisation spreads fixed costs, so profit can keep growing faster than sales.
  • Consumer demand: rising spending on personal care products in India supports long-term volume growth.
  • Low valuation: a P/E of about 16.8 is roughly half the industry average of 33.4.

Key Risks in the Aarti Surfactants Analyst Review 2027

  • Raw material swings: fatty alcohol and petrochemical prices can squeeze spreads quickly.
  • Customer concentration: a few large consumer brands account for much of demand.
  • History of thin margins: margins were near 5% for much of FY26, and could slip back.
  • Low returns so far: trailing return on equity is about 5%.
  • Debt: debt to equity of about 0.43 needs watching as working capital grows with sales.
  • Liquidity and coverage: thin trading and no research coverage can cause sharp price swings.

Compare Aarti Surfactants With Specialty Chemical Peers on the Univest Screener

Aarti Surfactants Analyst Review 2027: Stock at a Glance

Metric Value
Share Price (16 Nov 2026 close) ₹582.75
52-Week High / Low ₹677.70 / ₹316.00
Market Capitalisation ₹492 crore
P/E (TTM) vs Industry 16.8 vs 33.4
Price to Book 1.85
Book Value per Share ₹313.34
Return on Equity 5.04%
Debt to Equity 0.43
FY26 Revenue / Net Profit ₹859.5 crore / ₹12.3 crore

The trailing figures understate the change. Trailing return on equity of about 5% includes weak FY26 quarters; if the first-half run rate holds, the Aarti Surfactants analyst review 2027 suggests returns would rise sharply over FY27.

Shareholding Trend

Holder Sep 2025 Sep 2026 Change
Promoters 49.92% 49.84% -0.08 pts
Foreign Investors (FII) 0.00% 0.27% +0.27 pts
Domestic Institutions (DII) 0.80% 0.00% -0.80 pts
Public 49.29% 49.90% +0.61 pts

The promoter group, including Nikhil Holdings at 14.85% and Jaya Chandrakant Gogri at 13.6%, holds just under 50%. The small domestic institutional stake was sold during the year, and a tiny foreign stake appeared. Public holders own about half the company, which makes retail sentiment important in the Aarti Surfactants analyst review 2027.

Univest iOS App

Univest Android App

What to Watch After the Aarti Surfactants Analyst Review 2027

  • Q3 FY27 margin: whether operating margin stays near 9%.
  • Revenue trend: a fifth straight quarter of growth would confirm the recovery.
  • Raw material prices: fatty alcohol costs and the ability to pass them on.
  • Specialty mix: growth in higher-value personal care ingredients.
  • Research initiation: a first named report would set an Aarti Surfactants share price target 2027 benchmark.

Final Word on the Aarti Surfactants Analyst Review 2027

The Aarti Surfactants analyst review 2027 shows a small chemical maker in a clear upswing. Revenue has grown for four quarters, margins have risen from about 5% to almost 9%, and first-half profit already exceeds the whole of FY26. The stock still trades at about half the industry P/E.

The risks are those of a small, commodity-linked business: raw material swings, customer concentration and no research coverage. For the Aarti Surfactants stock outlook 2027, holding margins near current levels through the second half is the main test. Univest does not give a buy or sell call.

Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.

Frequently Asked Questions

What does the Aarti Surfactants analyst review 2027 show?

It shows Q2 FY27 revenue up about 63% to ₹291.4 crore and profit up to ₹12.5 crore from ₹1.56 crore. Operating margin rose to 8.8% from 5.3%. First-half profit of about ₹21.5 crore already exceeds FY26’s full-year ₹12.3 crore.

Is there an Aarti Surfactants share price target 2027 from brokerages?

No verified brokerage target exists for Aarti Surfactants as of November 2026. We found no dated report from a named research firm. The stock closed at ₹582.75 on 16 November 2026.

Why did profit jump in the Aarti Surfactants analyst review 2027 quarter?

Revenue grew strongly while fixed costs stayed largely flat, so EBITDA more than tripled to ₹30.0 crore from ₹9.4 crore. Operating margin improved by about 3.5 points. Earnings per share rose to about ₹14.75 from ₹1.84.

What does Aarti Surfactants make?

It makes surfactants, the cleaning and foaming ingredients used in shampoos, body washes, detergents and dishwashing liquids. It also makes specialty personal care ingredients. Its subsidiary Aarti HPC handles contract and private label manufacturing.

Is Aarti Surfactants undervalued, according to the Aarti Surfactants analyst review 2027?

The stock trades at a P/E of about 16.8, roughly half the industry figure of 33.4. Price to book is 1.85 on a book value of ₹313.34 per share. Trailing return on equity of about 5% is low, but recent quarters are much stronger.

What risks does the Aarti Surfactants analyst review 2027 highlight?

Raw material price swings, customer concentration and the risk of margins slipping back towards 5% are the main concerns. Debt to equity is about 0.43. Thin trading and no research coverage can also cause sharp price moves.

What should investors track after the Aarti Surfactants analyst review 2027?

Track whether operating margin holds near 9% and whether revenue grows for a fifth straight quarter. Watch fatty alcohol prices and the share of specialty products. The stock is about 14% below its 52-week high of ₹677.70.



2027 Aarti Surfactants Analyst Review Chemicals
Author: Ankit Jaiswal
Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.

Leave a Reply Cancel reply